Ampio Pharma: Drops on planned stock offering

Ampio Pharmaceuticals

17/06/2019 12:47

** Ampio Pharmaceuticals  AMPE.N  down 17% to 58 cents/sh
premarket as co looks to raise equity
    ** After the bell Fri, co announced follow-on for working
capital, general corp purposes, including funding clinical
trial; deal size not disclosed  urn:newsml:reuters.com:*:nPn9XWCzma
    ** ThinkEquity, Fordham Financial Management, Inc. division,
acting as sole bookrunner for offering
    ** Co has ~111.1 mln shares outstanding for market cap of
~$78 mln, per Refinitiv data
    ** Early Fri, co said it received FDA approval of its
special protocol assessment (SPA) of a clinical protocol for
lead drug Ampion  urn:newsml:reuters.com:*:nPn1hfQcpa
    ** Ampion is an injectable drug being developed to treat
severe osteoarthritis of the knee
    ** AMPE shares up 77% YTD following 90% plunge in 2018

 ((lance.tupper.tr.com@reuters.net
lance.tupper@tr.com 646-223-5017))